Two to buy
Vestas
(Investors Chronicle) Denmark’s Vestas has installed almost a fifth of the world’s wind-turbine capacity outside China. It is the world’s top supplier of onshore turbines. Government subsidies to the “green” economy have made wind power more popular, but increased competition has squeezed margins. That problem should subside this year, however, and “momentum is building in higher-margin servicing” post-installation. The company has been debt-free since 2013 and has over £1bn of net cash. A valuation of 26 times 2021 earnings is reasonable given the auspicious long-term outlook. 943kr
Pernod Ricard
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
(The Times) France’s Pernod Ricard is the world’s second-biggest drinks group behind Diageo. Activist investor Elliott Advisors had been pressing it to merge with a large rival to improve operating margins, but CEO Alexandre Ricard – whose family hold 14.2% of shares and 20.1% of the voting rights – gave the idea “short shrift”. However, he is following a policy of “bolt-on acquisitions” and improving margins is part of his plan. Despite Covid-19 and a €999m writedown (largely due to Absolut Vodka, which relies on airport sales), it has increased its market share while profits have fallen less than expected. €142
Two to sell
J Sainsbury
(Investors Chronicle) The supermarket group had steadied the ship after the pricey failed merger with Asda, but the pandemic has brought new problems, notably a squeeze on margins amid a shift towards less profitable online sales and large potential losses at its bank. The balance sheet remains “stretched”. The shares are inexpensive, but the growing army of short-sellers is right to sense “a value trap”. 213p
FirstGroup
(The Times) “There is... no case for investing in a UK public transport stock.” This train and bus operator has not paid a dividend since 2013 and is struggling to cope with its debt load. And don’t count on matters improving. The sale of its US operations, first announced in March, will produce little money and Britain’s semi-privatised railway system looks likely to be scrapped. Bus systems need massive investment. Avoid. 50p
...and the rest
The Daily Telegraph
Aviva’s new CEO Amanda Blanc aims to reform the underperforming insurance giant. Its “decent digital capability” and strong balance sheet bode well. Covid-19-related claims may inflate premiums. Buy (274p). Cable-assemblies maker Volex “has put its house in order and profits have responded”. Hold (189p).
Investors Chronicle
Derwent London “was one of the few commercial property groups to increase its dividend in the wake of Covid-19”. A solid balance sheet allows it to shrug off “short-term pain on rent collection”. Buy (310p).
Shares
Inspecs, an Aim-listed eyewear-frame maker, offers an appealing “growth story”. People will be rushing to catch up on eye appointments now that lockdown has lifted and there are still 2.6 billion people worldwide who need their vision corrected. Buy (230p).
-
8 of the best houses for sale with annexesThe best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
-
Zelenskyy moves to appease Donald Trump – what happens now?Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fadesFood-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
-
Should investors stay bullish and buy UK and US stocks?Opinion Ignore the Eeyores, says Max King. The outlook for stocks in both Britain and America remains auspicious
